{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T04:05:31Z","timestamp":1794197131940,"version":"4.8.0"},"reference-count":51,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T00:00:00Z","timestamp":1375401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U44NS065518"],"award-info":[{"award-number":["U44NS065518"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG000096"],"award-info":[{"award-number":["AG000096"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Clinical trials with passive and active Alzheimer's disease (AD) vaccines suggest that early interventions are needed for improvement of cognitive and\/or functional performance in patients, providing impetus for the development of safe and immunologically potent active vaccines targeting amyloid \u03b2 (A\u03b2). The AN\u20101792 trial has indicated that A\u03b2\u2010specific T cells may be unsafe for humans; therefore, other vaccines based on small A\u03b2 epitopes are undergoing preclinical and clinical testing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Humoral and cellular immune responses elicited in response to a novel DNA epitope\u2010based vaccine (AV\u20101955) delivered to rhesus macaques using the TriGrid electroporation device were evaluated. Functional activities of anti\u2010A\u03b2 antibodies generated in response to vaccination were assessed <jats:italic>in\u00a0vitro<\/jats:italic>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>AV\u20101955 generates long\u2010term, potent anti\u2010A\u03b2 antibodies and cellular immune responses specific to foreign T\u2010helper epitopes but not to self\u2010A\u03b2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This translational study demonstrates that a DNA\u2010based epitope vaccine for AD could be appropriate for human clinical testing.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jalz.2013.04.505","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T10:30:50Z","timestamp":1375266650000},"page":"284-295","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Epitope\u2010based DNA vaccine for Alzheimer's disease: Translational study in macaques"],"prefix":"10.1002","volume":"10","author":[{"given":"Claire F.","family":"Evans","sequence":"first","affiliation":[{"name":"Ichor Medical Systems San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayk","family":"Davtyan","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine Huntington Beach CA USA"},{"name":"Institute for Memory Impairments and Neurological Disorders University of California Irvine Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Petrushina","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders University of California Irvine Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Hovakimyan","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine Huntington Beach CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpine","family":"Davtyan","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine Huntington Beach CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Hannaman","sequence":"additional","affiliation":[{"name":"Ichor Medical Systems San Diego CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Cribbs","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders University of California Irvine Irvine CA USA"},{"name":"Department of Neurology University of California Irvine Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Agadjanyan","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine Huntington Beach CA USA"},{"name":"Institute for Memory Impairments and Neurological Disorders University of California Irvine Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[{"name":"Department of Molecular Immunology Institute for Molecular Medicine Huntington Beach CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,2]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.2174\/156720508784533321"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006296"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1372"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2101"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2010.02315.x"},{"key":"e_1_2_6_9_2","first-page":"628070","article-title":"Targeting beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease","volume":"2012","author":"Lobello K.","year":"2012","journal-title":"Int J Alzheimers Dis"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/187152709787847298","article-title":"Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy","volume":"8","author":"Ghochikyan A.","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2008.10.011"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"e_1_2_6_13_2","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","article-title":"Reversible memory loss in a mouse transgenic model of Alzheimer's disease","volume":"22","author":"Kotilinek L.A.","year":"2002","journal-title":"J Neurosci"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1580"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700088200"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3201-07.2007"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD\u2010like pathology in 3xTg\u2010AD mouse model by DNA epitope vaccine: a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan N.","year":"2008","journal-title":"PLoS ONE"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000333359"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.42"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-1-4614-5380-2_9","volume-title":"Novel immune potentiators and delivery technologies for next generation vaccines","author":"Evans C.F.","year":"2013"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.08.016"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.8.4884-4887.2004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm099"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20592"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.140"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-2-18"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1479-5876-9-127","article-title":"The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease","volume":"9","author":"Davtyan H.","year":"2011","journal-title":"J Transl Med"},{"key":"e_1_2_6_28_2","first-page":"109","article-title":"DNA vaccines: recent technological and clinical advances","volume":"6","author":"Ulmer J.B.","year":"2006","journal-title":"Discov Med"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019252"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.11.6448"},{"key":"e_1_2_6_31_2","unstructured":"Eli Lilly and Company announces top\u2010line results on solanezumab phase 3 clinical trials in patients with Alzheimer's disease August 24 2012. Available at:http:\/\/newsroom.lilly.com\/releasedetail.cfm?releaseid=702211. Accessed May 31 2013"},{"key":"e_1_2_6_32_2","unstructured":"Johnson & Johnson announces discontinuation of phase 3 development of bapineuzumab intravenous (IV) in mild\u2010to\u2010moderate Alzheimer's disease August 6 2012. Available at:http:\/\/www.jnj.com\/connect\/news\/all\/johnson\u2010and\u2010johnson\u2010announces\u2010discontinuation\u2010of\u2010phase\u20103\u2010development\u2010of\u2010bapineuzumab\u2010intravenous\u2010iv\u2010in\u2010mild\u2010to\u2010moderate\u2010alzheimers\u2010disease. Accessed May 31 2013."},{"key":"e_1_2_6_33_2","unstructured":"RSperling SSalloway MARaskind SFerris ELiu EYuen et\u00a0al.A randomized double\u2010blind placebo\u2010controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E \u03b54 carriers.Presented at the 16th Congress of the European Federation of Neurological Societies; September 8\u201011 2012;Stockholm Sweden."},{"key":"e_1_2_6_34_2","unstructured":"SSalloway RSperling LHonig APorsteinsson MSabbagh ELiu et\u00a0al.A randomized double\u2010blind placebo\u2010controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E \u03b54 non\u2010carriers.Presented at the 16th Congress of the European Federation of Neurological Societies; September 8\u201011 2012;Stockholm Sweden."},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.2174\/187152710791012080"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.136"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2007.06.006"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.031"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0293-11.2011"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70140-0"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.220.95"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2009.219"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07458.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.11.13217"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200401000-00009"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63296-8"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.05.012"},{"key":"e_1_2_6_48_2","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3233\/JAD-2010-100978","article-title":"Assessment of non\u2010viral amyloid\u2010beta DNA vaccines on amyloid\u2010beta reduction and safety in rhesus monkeys","volume":"22","author":"Tokita Y.","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"e_1_2_6_49_2","first-page":"660","article-title":"Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease\u2010associated beta\u2010amyloid 1\u201315 peptide vaccine","volume":"118","author":"Li S.","year":"2005","journal-title":"Chinese Med J"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.03.008"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4672-12.2013"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2011.09.006"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526013006560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526013006560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2013.04.505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2013.04.505","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2013.04.505","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2013.04.505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:55:14Z","timestamp":1759856114000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2013.04.505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,2]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1016\/j.jalz.2013.04.505"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2013.04.505","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,2]]},"assertion":[{"value":"2013-08-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}